- US firm Sparta Pharmaceuticals' new leukemia treatment, Spartaject busulfan, will be developed and commercialized in the European market by Orphan Europe SARL of France, and Swedish Orphan AB. Orphan Europe has rights in western Europe while Swedish Orphan has rights in Scandinavia. Sparta's lipid-based Spartaject technology facilitates the injection of drugs that are difficult to solubilize in water. Busulfan is currently given by mouth to patients with chronic leukemia, but requires the ingestion of large numbers of tablets. Given by this route, absorption of the drug is highly variable and can lead to serious side effects. Spartaject busulfan is also in Phase I for preoperative chemotherapy in bone marrow transplants.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze